GBT Announces New Employment Inducement Grants
August 07 2020 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced
that on August 1, 2020, the compensation committee of GBT’s board
of directors granted seven new employees options to purchase an
aggregate of 9,750 shares of the company’s common stock with a per
share exercise price of $67.48 and restricted stock units for an
aggregate of 55,675 shares of the company’s common stock. These
awards were made under GBT’s Amended and Restated 2017 Inducement
Equity Plan (the Plan). Pursuant to the Plan, the exercise price
for the 9,750 shares of the company’s common stock was the closing
trading price on July 31, 2020, because there was no closing
trading price on August 1, 2020.
The above-described awards were each granted as an inducement
material to the employees entering into employment with the company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Plan was adopted by GBT’s
board of directors in January 2017 and has been amended and
restated from time to time.
About Global Blood Therapeutics Global
Blood Therapeutics (GBT) is a biopharmaceutical company dedicated
to the discovery, development, and delivery of life-changing
treatments that provide hope to underserved patient communities.
Founded in 2011, GBT is delivering on its goal to transform the
treatment and care of sickle cell disease (SCD), a lifelong,
devastating inherited blood disorder. The company has introduced
Oxbryta® (voxelotor), the first FDA-approved treatment that
directly inhibits sickle hemoglobin polymerization, the root cause
of red blood cell sickling in SCD. GBT is also advancing its
pipeline program in SCD with inclacumab, a p-selectin inhibitor in
development to address pain crises associated with the disease. In
addition, GBT’s drug discovery teams are working on new targets to
develop the next generation of treatments for SCD. To learn more,
please visit www.gbt.com and follow the company on Twitter
@GBT_news.
Contact Information:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Stephanie Yao (investors)650-741-7730syao@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024